cyrilzakka/clinical-trials huggingface dataset:
Comparison Between Methyl Prednisolone and Intravenous Dexamethazone in Severe Immune Thrombocytopenic Purpra

Immune thrombocytopenic purpra(ITP) is an autoimmune thrombocytopenic syndrome characterized by decreased platelet count and increased risk of bleeding, primarily due to immunoglobulins G(IgG)autoantibodies opsonizing the individual's platelets,resulting in markedly enhanced Fc receptors(FcR)-mediated phagocytosis and destruction by macrophages in the reticuloendothelial system within spleen Severe ITP defined as :Patients who have clinically relevant bleeding that mean that patients have bleeding symptoms at presentation sufficient to mandate treatment,or occurrence of new bleeding symptoms requiring additional therapeutic intervention with a different platelet-enhancing agent or an increased dose.

Immune thrombocytopenic purpra(ITP) is an autoimmune thrombocytopenic syndrome characterized by decreased platelet count and increased risk of bleeding, primarily due to immunoglobulins G(IgG)autoantibodies opsonizing the individual's platelets,resulting in markedly enhanced Fc receptors(FcR)-mediated phagocytosis and destruction by macrophages in the reticuloendothelial system within spleen Severe ITP defined as :Patients who have clinically relevant bleeding that mean that patients have bleeding symptoms at presentation sufficient to mandate treatment,or occurrence of new bleeding symptoms requiring additional therapeutic intervention with a different platelet-enhancing agent or an increased dose.Prednislone is the standard intial first-line therapy in naïve ITP patients.Prednislone is usually given at 0.5 to 2mg/kg until platelet count increase(\>30-50 \*10\^9/L )which may require several days to several weeks,however prednisone should be rapidly tapered after 4 weeks to avoid corticosteroid related complication. In a trial to shorten the duration and reduce adverse effects of corticosteroids treatment. Dexamethasone in a dose of 40mg/day has been administered for 4days (equivalent to\~400mg of prednisone per day) achieved 85% initial reponse and sustained response 50% of adult cases of ITP at 6 months follow up

Eligibility Criteria:
Inclusion Criteria:

* Patients were aged 18or older diagnosed as acute severe ITP presented with active bleeding for emergency treatment.

Exclusion Criteria:

* Any contraindications for steroid therapy (osteoprosis, uncontrolled diabetes or uncontrolled hypertension).
MiRNAs Evaluate the Prognosis of Sepsis

Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to screen several miRNA by microarray which evaluate the sepsis prognosis in order to be a new target for the treatment of sepsis.

The study is a non-intervention, prospective observational study. Purpose of this sudy is to screening several miRNAs by microarray which can evaluate the prognosis of sepsis . We will collect serum samples from patients with sepsis in SICU, RICU and EICU of 301 Hospital since September 2009 , and then use the chip and qRT-PCR to Screen miRNAs which can evaluate the prognosis of sepsis, and statistical analysis the miRNAS expression correlation with SOFA score.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of sepsis
* Patients who agree with the study

Exclusion Criteria:

* Aged \<18 years;
* Into the group who died within 24 hours;
* Agranulocytosis (\<0.5 × 109 / L);
* Combined HIV infection.
The Pectoral Block for Breast Augmentation Surgery

The pectoral block is a recently developed regional anesthetic technique that can be used for the treatment of postoperative pain after breast surgery. Injection of local anesthetic between the major and the minor pectoral muscles is defined as the pectoral (PEC) 1 block. This block has not been well characterized in terms of its blocking effects on motor and sensitive nerves (medial and lateral pectoral nerves and intercostal nerves). This clinical trial is divided into two sections: a volunteer study and a patient study.

For the volunteer study, the aim is to assess the sensory territory affected by injection of local anesthetics through a PEC 1 block and to assess motor function in terms of strength of adduction of the affected limb using a dynamometer.

In a prospective, randomized, controlled and double blind study, the aim is to assess the postoperative pain relieving properties of the PEC 1 block in patients undergoing bilateral breast augmentation surgery.


Eligibility Criteria:
Inclusion Criteria:

* breast augmentation surgery
* registration at régie d'assurance maladie du Québec (RAMQ) (social services)

Exclusion Criteria:

* known bleeding disorder
* anticoagulant intake
* infection at site of PEC 1 block
* pregnant or breast-feeding women
* allergy to bupivacaine
* chronic pain including fibromyalgia with regular analgesic consumption
* under recreational drugs or alcohol at doses above canadian recommendations
* muscle relaxants intake
* patients already operated for breast augmentation or mastectomy
A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)

This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with perennial allergic rhinitis. The primary hypothesis is that desloratadine is superior to placebo after 2 weeks of treatment with regard to change from baseline in Total Nasal Symptom Score among Japanese participants with perennial allergic rhinitis.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with perennial allergic rhinitis
* Outpatient.

Exclusion Criteria:

* Lower respiratory tract infection or nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.)
* Coexisting infections or systemic mycosis for which there are no effective antibiotics
* Asthma complication under treatment
* Nasal septum ulcers, nasal surgery, or nasal trauma, which has not healed
* Vasomotor rhinitis or eosinophilic rhinitis
* Nasal conditions (infectious sinusitis, hypertrophic rhinitis, acute or chronic rhinitis, nasal polyps, septal deviation, etc.) which may interfere with the evaluation of the efficacy of the study drug
* History of hypersensitivity to antihistamines or study drug
* Currently receiving treatment with another investigational drug or has received an investigational drug in the past 3 months
* Has started specific desensitization therapy or nonspecific allassotherapy (Histaglobin, vaccine therapy, etc.) or who had discontinued such therapies within 90 days (3 months) before the day of obtaining informed consent
* Severe hepatic, renal, cardiac, hematological disease, or other serious coexisting diseases and whose general condition is poor
* History of malignancy or clinically important hematological disorder
* History of severe drug allergy (e.g., anaphylactoid reaction).
Effect of Smart Watch and App on PAP Adherence in OSA (Watch-OSA)

Continuous positive airway pressure (CPAP) is highly effective in treating obstructive sleep apnea (OSA). However, this treatment modality relies heavily on patient adherence, and poor adherence to the treatment limits its effectiveness in treating OSA. Strategies to augment adherence are needed in the management of OSA.

The smart watch and linked app provide various health information, including sleep, snoring or oxygen saturation during sleep, exercise, blood pressure, and electrocardiogram. The smart watch and linked app could potentially improve adherence to positive airway pressure (PAP) treatment.

This randomized controlled trial (RCT) aimed to examine whether the use of smart watch and app can increase PAP adherence in patients with OSA.


Eligibility Criteria:
Inclusion Criteria:

* diagnosed with OSA (apnea-hyponea index \[AHI\])≥ 5 /h) by type 1 polysomnography
* no prior use of PAP (CPAP or auto-adjusting PAP \[APAP\]), or no prior use of PAP within the previous 90 days in patients who had received PAP therapy, or current PAP users with average daily usage (all days) \< 4 hours within the previous 90 days

Exclusion Criteria:

* patients who refuse PAP therapy
* patients who have used a smart watch (e.g., Galaxy Watch, Apple Watch, etc.) within the previous 90 days
* patients with central sleep apnea or neuromuscular disease
* patients receiving supplemental oxygen therapy due to underlying diseases including heart failure, stroke, chronic obstructive pulmonary disease, interstitial pulmonary disease, hypoventilation syndrome, or whose baseline oxygen saturation is less than 90%
* patients with implanted cardiac pacemakers, defibrillators, or other electronic devices
* patients who are inexperienced in using smartphones, apps, or smart watches
* patients with an inability or unwillingness to provide informed consent
Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)

Cardiovascular morbidity and mortality is high in CKD patients. Nitric oxide (NO) deficiency plays a crucial role in progression of CKD. This leads to endothelial dysfunction, hypertension, and inflammation. Hydrogen sulfide (H2S) could serve as a backup mechanism for NO deficiency in CKD. N-acetylcysteine (NAC) is a derivate of cysteine and this is the main substrate for H2S production. Therefore, NAC should enable us to stimulate H2S production in humans. Our objective is to investigate the effect of NAC on plasma H2S levels and on markers of oxidative stress, inflammation, and endothelial dysfunction in healthy volunteers, CKD patients, and dialysis patients. We hypothesize that there is an increase in H2S levels after treatment with NAC.


Eligibility Criteria:
Inclusion criteria:

Healthy volunteers:

* Adult (\> 18 years and older)
* Healthy, as assessed by medical history, blood pressure, plasma creatinine, and urine dipstick
* No medication use

CKD patient:

* Adult (\> 18 years and older)
* CKD stage 3-4 (GFR 15-60 ml/min)

Hemodialysis patient:

* Adult (\> 18 years and older)
* Hemodialysis patient

Peritoneal dialysis patient:

* Adult (\> 18 years and older)
* Peritoneal dialysis patient

Exclusion criteria:

* Unable to give informed consent
* Hypersensitivity to N-acetylcysteine
* Pregnancy
Impact of Rapeseed and Sunflower Oils on Proteomic Biomarkers of Diseases.

This study will test the impact of vegetable oils with contrasting fatty acids composition on biomarkers of health (cardiovascular, kidney diseases and diabetes) after twelve weeks supplementation. We will use sunflower oil (high in PUFAs), rapeseed oil (high in MUFAs, locally produced) and a non-intervention control. We have developed a sensitive and selective urinary proteomic biomarker of cardiovascular disease which we will use in a double-blinded randomised study.

The intervention follows a parallel double-blind randomised control design. The intervention duration is 12 weeks, with a mid-point assessment at 6 weeks. Randomisation to groups; rapeseed oil, sunflower oil or habitual diet is performed using a block stratified allocation based on age (under or over 45) and BMI (under or over 30kg/m2) and is carried out remotely via phone.

Participants allocated to either oil groups are instructed to consume the oils uncooked, as a partial replacement to their habitual fat intake. Participants in the control group are asked to not change any aspect of their diet.

Spot urine samples are collected from all participants at all time points for measurement of the primary outcome (proteomic biomarker score). Urine is collected in a plastic tube, mid-flow, as the second urination of the day at baseline, 6 and 12 weeks.

Fasting venous blood is collected for the assessment of secondary outcomes, at baseline, 6 weeks and 12 weeks. Participants are also asked to complete a 2-day food diary at weeks 0, 6 and 12

Eligibility Criteria:
Inclusion Criteria:

* Overweight adults with a BMI\>25 and/or a large waist (Male \>102cm and female \>88cm),
* Aged 25-75 years
* No history of chronic disease of the GI tract
* Not taking medication (other than the contraceptive pill).

Exclusion Criteria:

* Pregnant or lactating
* Allergy to any vegetable oils and vegetable oil-derived products
Mycoplasma Genitalium Infection and Associated Antimicrobial Resistance Among HIV-infected Male in Hong Kong

Worldwide, Mycoplasma genitalium (MG) is increasingly reported as an emerging cause of sexually transmitted infections. Internationally, the prevalence of MG is higher in male with urethritis and community groups especially among people living with HIV (PLHIV). While MG is treatable, antimicrobial resistance is a rising concern. This cross-sectional study aims to determine the prevalence of MG infection and the antimicrobial resistance pattern in HIV-infected male in Hong Kong.

A total of 750 HIV-infected male attending HIV specialist clinic in Hong Kong would be recruited. The main outcome measures include prevalence of MG and resistance mutations to macrolide/fluoroquinolone in HIV-infected male; prevalence of MG/STI co-infections, as defined by concurrent detection of MG and one or more other bacterial STI.

A total of 750 HIV-infected male attending HIV specialist clinic in Hong Kong would be recruited. An online questionnaire would be self-administered. The participants would self-collect urine sample, rectal and pharyngeal swabs for MG, Chlamydia trachomatis (CT) and Neisseria Gonorrhoeae (NG) screening by nucleic acid amplification tests, and MG genotypic resistance mutations detection. Clinical data would be transcribed from medical records of recruited subjects.

Eligibility Criteria:
Inclusion Criteria:

* aged 18 or older, male, HIV-infected, and are attendees of the HIV specialist clinic, and can communicate in written and spoken English or Chinese

Exclusion Criteria:

* not able to provide consent
The Influence of Age and Gender on Tongue Pressure and Swallowing Tongue Pressure

The main topic of the research is to investigate the tongue's strength when swallowing. There has been much foreign literature on tongue strength. Iowa Oral Performance Instrument also has norms for reference, but the data are all taken from non-Asian people such as Caucasians. In this case, the credibility of the norms are decreased in domestic, and we also lack norm data of tongue strength when swallowing. Through the research, we can establish normative data belonging to the domestics, provide usable data for domestic researchers and clinical staff, and explore whether there are differences in age and gender in data between Taiwanese and foreigners.

Swallowing refers to the process by which food enters the stomach from the mouth. It is the physiological mechanism by which humans take in water and nutrients. It is a vital activity for individual survival. The physiological mechanism of swallowing has four major stages, oral preparation, oral cavity, pharynx, and esophagus. Each stage has its physiological mechanism, which depends on the different nerve and muscle structures. In the oral stage, our tongue plays an important role. Whether in the formation or transition of the food bolus, it must rely on the tongue to perform its normal functions. The main topic of the research is to explore the strength of the tongue when swallowing. The purpose is to discuss the influence of gender and age on swallowing tongue pressure. We expect to recruit 80 subjects and divide them into three groups according to their age: 20 to 39 years old, 40 to 59 years old, and 60 to 79 years old, with 13 to 14 males and females in each group, using Iowa Oral Performance Instrument measures the subject's maximum tongue pressure, average swallowing tongue pressure, and the ratio of the maximum tongue pressure used when swallowing, to explore whether age and gender affect tongue strength when swallowing.

Eligibility Criteria:
Inclusion Criteria:

* Aged twenty and above.

Exclusion Criteria:

* Based on self-representation, has the disease of the nervous system, included stroke, brain trauma, Parkinson's disease, dementia, etc.
* Based on self-representation, has head and neck cancers.
* Based on self-representation, had any history of swallowing disorders.
* Based on self-representation, has obvious cognition impairment or language disorder that will affect measure procedure.
Toddlers' Responses to Strangers

The study will assess if toddlers show differences in stranger wariness according to race, temperament, social network diversity, and neighborhood diversity.

This study is investigating 13- to 24-month-old toddlers' reactions to meeting new people from familiar and unfamiliar racial backgrounds! Participation involves a 1-hour one-time visit to the researcher's lab, located on the UC Santa Cruz campus.

The study itself will take about 20 minutes, but will ask for a 1-hour visit to make sure child participants feel comfortable in the new space. The study will video record as child participants interact with two adults, who will play with the child and offer toys. Parent participants will also be asked to complete two surveys, one demographic survey and one social network survey, so that investigators can better understand how the people children see in their daily lives relate to how participants react to strangers from different racial backgrounds.

Eligibility Criteria:
Inclusion Criteria:

* typically developing
* age 13-24 months

Exclusion Criteria:

- any known developmental delays
Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia

The purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophrenia


Eligibility Criteria:
Inclusion Criteria:

* Patients with DSM-IV diagnosis of schizophrenia patients in acute relapse
* Treated as outpatients for at least one continuous 3-month period during the past 12 months
* PANSS total score ≥60
* Previously responsive to neuroleptics (other than clozapine)
* Able to give informed consent and comprehend and satisfactorily comply with the protocol requirements

Exclusion Criteria:

* An Axis I (DSM-IV) diagnosis of schizoaffective disorder
* A clinical picture and/or history that was consistent with: (a) Delirium, dementia, amnestic or other cognitive disorders; (b) Bipolar disorder; (c)personality disorder
* Nonresponsive to prior olanzapine therapy
* Likely to require prohibited concomitant therapy
* DSM-IV criteria for any significant substance abuse within the past three months, including addiction to cocaine or alcohol
* Known to be allergic or hypersensitive to study drugs
* Represented a significant risk of committing suicide based on history or mental status exam
* Unstable thyroid pathology and treatment within the past six months
* A history or evidence of a medical condition that would expose the patient to an undue risk
* Clinically significant abnormal laboratory test results (including urine drug screen), vital sign, or ECG findings
Ovarian Cancer Radiomics Approach in CT Led Evaluation

When patients have suspected or confirmed ovarian cancer standard treatment will involve surgery and chemotherapy. However, as with any treatment, it is challenging to predict treatment response in advance. Before treatment, all patients have a CT scan to describe where the cancer is in order to guide the treatment.

There is now a new way to analyse routine scans using advanced computing methods, which may give more information about the ovarian cancer. This is called radiomics which analyses features in scans that are not visible to the naked eye. Our group at Imperial College London has worked on developing radiomic models to better understand ovarian cancer.

This study aims to determine whether the information gained from this new approach would help us to tailor patient treatment plans to better meet the patient's individual needs, even more than done already. Furthermore, the aim is to understand how different types of ovarian cancer can correlate with the radiomic findings, which may help develop potential treatments in the future.


Eligibility Criteria:
Inclusion Criteria:

* Written (signed and dated) informed consent
* Age 18 years or over
* Suspected or confirmed advanced epithelial ovarian cancer (FIGO stage 3B or more)
* Being considered for active anticancer treatment i.e. primary cytoreductive surgery followed by chemotherapy or neoadjuvant chemotherapy followed by interval cytoreductive surgery
* Evaluable baseline portal venous phase CT scan prior to surgical or medical treatment for ovarian cancer
* Disease visible on pre-treatment portal venous phase baseline CT scan (≥2cm)

Exclusion Criteria:

* Known contra-indication to CT with IV contrast (e.g. contrast allergy, renal failure, inability to lie flat);
* Unable to give informed consent;
* Known pregnancy;
* No visible disease \<2cm on portal venous phase baseline CT scan;
* Previous surgery for resection of an adnexal mass;
* Significant artefact on CT image for example from metal prostheses that precluded meaningful segmentation of visible disease
* Only fit for palliative care at initial presentation
CABG Based on CT-FFR Versus Conventional Coronary Angiography

The aims of study are (1) to compare early and 1-year graft patency rates in patients who underwent coronary artery bypass grafting (CABG) based on conventional coronary angiography(CAG) versus cardiac computed tomography(CT)-derived fractional flow reserve(FFR), and (2) to demonstrate difference in clinical outcomes between the 2 groups.

The CABG-COREA trial is designed as a randomized, controlled trial to recruit 96 patients who undergo coronary artery bypass grafting. Patients were randomized by use of a randomization table. Coronary arteries are revascularized based on conventional coronary angiography (quantitative coronary angiography) or cardiac computed tomography-derived fractional flow reserve according to the randomization result.

The primary end point is to evaluate early and 1-year postoperative graft patency. The secondary end points are overall survival, freedom from cardiac death and freedom from MACCE(major adverse cardiac or cerebrovascular events).

Eligibility Criteria:
Inclusion Criteria:

* age equal or more than 40
* age equal or less than 80
* patients who undergo coronary artery bypass grafting due to multi-vessel coronary artery disease
* patients who agree to the enrollment

Exclusion Criteria:

* Patients with heart failure (left ventricular ejection fraction \< 25%)
* patients who have intractable ventricular arrhythmia
* patients who has been treated for cancer
* patients who has infectious disease
* patients who are planned to undergo combined cardiac surgery
* patients who has medical co-morbidity with expected survival less than 1 year
* patients with a history of previous cardiac surgery
* Patients with chronic renal failure requiring dialysis
* patients who undergo emergency operation